#USA #Kessler Topaz #Radnor #ImmunityBio #IBRX

Overview

ImmunityBio, Inc. (IBRX) has drawn the attention of the legal community following the recent filing of a class action lawsuit alleging securities fraud. The lawsuit pertains to the experiences of investors who purchased IBRX securities from January 19, 2026, to March 24, 2026. The deadline for those affected to seek lead plaintiff status in this case is May 26, 2026.

What Happened?

The securities fraud allegations stem from claims made by ImmunityBio regarding its lead biologic product, Anktiva. Investors allege that the company made materially false statements or omissions about Anktiva's capabilities. Notably, the lawsuit postulates that ImmunityBio falsely claimed that Anktiva could cure and prevent cancer. These misrepresentations allegedly impacted investors' decisions and led to financial losses. Following a report by Bloomberg on March 24, 2026, which revealed that the FDA issued a warning letter to ImmunityBio, the company’s stock price plummeted, falling 21.12% in a single day.

Key Allegations in the Complaint

The class action complaint brings forward several significant allegations:
1. ImmunityBio misrepresented Anktiva as a cancer vaccine, which has been called into question.
2. The company’s leadership overstated the efficacy of Anktiva. The Executive Chairman and Global Chief Scientific and Medical Officer was quoted as making unverifiable claims regarding the product's ability to cure all cancer.
3. These false claims and omissions misled investors regarding the company's operational prospects, causing them to suffer financial losses.

Importance of the Class Action

Class action suits serve to consolidate individual investors' claims in situations where a larger group has faced similar issues. This particular case, filed in the United States District Court for the Central District of California under the title Douglas v. ImmunityBio, Inc., is guided by the principle of protecting investors and holding companies accountable for misleading actions. It provides a platform for the injured investors to seek redress collectively rather than navigating the legal system individually. Investors who have suffered losses can potentially recover damages through this action.

Next Steps for Affected Investors

Investors who purchased or acquired ImmunityBio securities during the specified period are urged to take immediate action:

• - Contact Legal Counsel: Kessler Topaz Meltzer & Check, LLP (KTMC) is ready to assist affected investors. Interested parties can inquire about their rights and options for participation in the legal proceedings without any obligation.
• - File for Lead Plaintiff Status: Those interested in taking on a lead plaintiff role must do so before the May 26, 2026 deadline. The lead plaintiff will represent the interests of the whole group in the litigation.

Conclusion

The allegations against ImmunityBio underscore the vital role that accountability plays in the market. For investors, now is the time to assess their positions and consider engaging with legal representation. For more information, investors can reach out to KTMC for assistance regarding the specific details of this lawsuit and their potential next steps. This class action marks an important moment in safeguarding investors' rights against potential corporate misconduct.

For more updates and discussions regarding ImmunityBio, interested parties can explore further resources available on KTMC’s website and stay informed through their investor communication channels.